CN1622831A - 促进核酸转移的方法 - Google Patents
促进核酸转移的方法 Download PDFInfo
- Publication number
- CN1622831A CN1622831A CNA028164008A CN02816400A CN1622831A CN 1622831 A CN1622831 A CN 1622831A CN A028164008 A CNA028164008 A CN A028164008A CN 02816400 A CN02816400 A CN 02816400A CN 1622831 A CN1622831 A CN 1622831A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- collagen
- complex
- cell
- composite particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
复合物 | 端胶原(%) | pDNA(μg/ml) |
EGFG-1 | 0 | 100 |
EGFG-2 | 0.001 | 100 |
EGFG-3 | 0.01 | 100 |
EGFG-4 | 0.05 | 100 |
EGFG-5 | 0.1 | 100 |
复合物 | 端胶原(%) | pDNA(μg/ml) |
EGFG-3A | 0.005 | 100 |
EGFG-3B | 0.008 | 100 |
EGFG-3 | 0.01 | 100 |
EGFG-3C | 0.015 | 100 |
EGFG-3D | 0.02 | 100 |
EGFG-3E | 0.03 | 100 |
仅pDNA | 0 | 100 |
复合物 | 端胶原(%) | pDNA(μg/ml) |
EGFG-3B | 0.008 | 100 |
EGFG-3B2 | 0.008 | 60 |
EGFG-3B3 | 0.008 | 40 |
EGFG-3B4 | 0.008 | 20 |
样品 | 质粒DNA | Solv. | C.C.(%) | 每C.M的N.M数 | 复合物的平均长轴(μm) | ||
混合后 | 70μm滤器过滤后 | 10μm滤器过滤后 | |||||
10-1 | pCMV-EGFP | 水 | 0.001 | 2406 | 9.1 | 8.9 | <3.4 |
10-2 | pCMV-EGFP | 水 | 0.005 | 742 | 37 | 26 | |
10-3 | pCMV-EGFP | 水 | 0.008 | 699 | 6.6 | ||
10-4 | pCMV-EGFP | 水 | 0.01 | 299 | 53 | 44 | 35 |
10-5 | pCMV-EGFP | 水 | 0.02 | 356 | 17 | ||
10-6 | pCMV-EGFP | 水 | 0.05 | 76 | 122 | 105 | |
10-7 | pCMV-EGFP | 水 | 0.1 | 66 | 303 | 174 | |
10-8 | pCMV-EGFP | PB | 0.001 | 448 | <3.4 | <3.4 | |
10-9 | pCMV-EGFP | PB | 0.01 | 152 | 7.7 | ||
10-10 | pCMV-EGFP | PB | 0.1 | 97 | 22 | 14 | |
10-11 | pCMV-EGFP | PBS | 0.01 | 300 | 13 | 9.2 | |
10-12 | pCMV-EGFP | PBS | 0.1 | 97 | 22 | 15 | |
10-13 | pCMV-HST-1-IL-2 | 水 | 0.001 | 4228 | 6 | 6.1 | <3.4 |
10-14 | pCMV-HST-1-IL-2 | 水 | 0.005 | 1122 | 20 | 9.8 | |
10-15 | pCMV-HST-1-IL-2 | 水 | 0.008 | 426 | 6.1 | ||
10-16 | pCMV-HST-1-IL-2 | 水 | 0.01 | 324 | 20 | 13 | 27 |
10-17 | pCMV-HST-1-IL-2 | 水 | 0.02 | 360 | 16 | ||
10-18 | pCMV-HST-1-IL-2 | 水 | 0.05 | 95 | 151 | 201 |
10-19 | pCMV-HST-1-IL-2 | 水 | 0.1 | 66 | 256 | 201 | |
10-20 | pCMV-HST-1-IL-2 | PB | 0.001 | 701 | 6.1 | <3.4 | |
10-21 | pCMV-HST-1-IL-2 | PB | 0.01 | 262 | 20 | ||
10-22 | pCMV-HST-1-IL-2 | PB | 0.1 | 97 | 25 | 9.4 | |
10-23 | pCMV-HST-1-IL-2 | PBS | 0.01 | 315 | 9.8 | ||
10-24 | pCMV-HST-1-IL-2 | PBS | 0.1 | 97 | 29 |
样品 | Solv. | O.C.(μM) | C.C.(%) | 每C.M的O.M数 | 每C.M的N.M数 | 复合物的平均长轴(μm) |
11-1 | 水 | 1.0 | 0.05 | 0.6 | 12 | 32 |
11-2 | 水 | 5.0 | 0.05 | 3 | 60 | 13 |
11-3 | 水 | 10.0 | 0.05 | 4.4 | 88 | 12 |
11-4 | 水 | 20.0 | 0.05 | 5.2 | 104 | 17 |
11-5 | 水 | 10.0 | 0.01 | 6.3 | 126 | 32 |
11-6 | 水 | 10.0 | 0.1 | 2.9 | 58 | 20 |
11-7 | PB | 1.0 | 0.05 | 0.5 | 10 | 25 |
11-8 | PB | 5.0 | 0.05 | 1.2 | 24 | 29 |
11-9 | PB | 10.0 | 0.05 | 1.4 | 28 | 35 |
11-10 | PB | 20.0 | 0.05 | 1.3 | 26 | 36 |
11-11 | PB | 10.0 | 0.01 | 3.3 | 66 | 23 |
11-12 | PB | 10.0 | 0.1 | 1.3 | 26 | 33 |
11-13 | PB | 10.0 | 0.5 | 0.5 | 10 | 46 |
11-14 | PB | 10.0 | 1.0 | 0.3 | 6 | 49 |
11-15 | PB | 10.0 | 1.5 | 0.2 | 4 | 54 |
样品 | 每个胶原分子所对应的核苷酸单体数 | 复合物的平均长轴(μm) | 转移效率 |
对照 | 0.0028 | ||
10-1 | 2406 | 9.1 | 0.0760 |
10-4 | 299 | 53 | 0.0729 |
10-7 | 66 | 303 | 0.0374 |
样品 | 细胞种类 | 溶剂 | FBS存在与否 | 每个胶原分子所对应的核苷酸单体数 | 复合物的平均长轴(μm) | 培养基中IL-2浓度(pg/ml) |
对照 | 293 | 水 | 存在 | 5.3 | ||
10-13 | 293 | 水 | 存在 | 4228 | 6 | 7.3 |
10-14 | 293 | 水 | 存在 | 1122 | 20 | 14.8 |
10-15 | 293 | 水 | 存在 | 426 | 6.1 | 19.3 |
10-16 | 293 | 水 | 存在 | 324 | 20 | 6.3 |
10-17 | 293 | 水 | 存在 | 360 | 16 | 18.2 |
10-18 | 293 | 水 | 存在 | 95 | 151 | 8.4 |
10-19 | 293 | 水 | 存在 | 66 | 256 | 5.3 |
对照 | 293 | PB | 不存在 | 23.55 | ||
10-20 | 293 | PB | 不存在 | 701 | 6.1 | 72.93 |
10-21 | 293 | PB | 不存在 | 262 | 20 | 264.61 |
10-22 | 293 | PB | 不存在 | 97 | 25 | 86.22 |
对照 | 293 | PB | 存在 | 3.35 | ||
10-20 | 293 | PB | 存在 | 701 | 6.1 | 21.01 |
10-21 | 293 | PB | 存在 | 262 | 20 | 86.68 |
对照 | 293 | PBS | 存在 | 1.07 | ||
10-23 | 293 | PBS | 存在 | 315 | 9.8 | 15.26 |
对照 | NIH3T3 | 水 | 存在 | 0 | ||
10-14 | NIH3T3 | 水 | 存在 | 1122 | 20 | 0.79 |
10-15 | NIH3T3 | 水 | 存在 | 426 | 6.1 | 6.06 |
10-16 | NIH3T3 | 水 | 存在 | 324 | 20 | 4.05 |
10-17 | NIH3T3 | 水 | 存在 | 360 | 16 | 2.78 |
样品 | 溶剂 | 每个胶原分子所对应的核苷酸单体数 | 复合物的平均长轴(μm) | 转移效率 |
对照 | 水 | 0.0012 | ||
10-1 | 水 | 2406 | 9.1 | 0.0231 |
10-4 | 水 | 299 | 53 | 0.0247 |
10-7 | 水 | 66 | 303 | 0.0041 |
样品 | 溶剂 | 每个胶原分子所对应的核苷酸单体数 | 复合物的平均长轴(μm) | 表达EGFP的细胞数 |
对照 | PB | 100 | ||
10-8 | PB | 448 | <3.4 | 128 |
10-9 | PB | 152 | 7.7 | 1200 |
10-10 | PB | 97 | 22 | 12000 |
样品 | 溶剂 | 每个胶原分子所对应的核苷酸单体数 | 复合物的平均长轴(μm) | 培养基中IL-2浓度(pg/ml) |
对照 | PB | 0 | ||
10-20 | PB | 701 | 6.1 | 8.98 |
10-21 | PB | 262 | 20 | 76.81 |
10-22 | PB | 97 | 25 | 120.74 |
Claims (21)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001186320 | 2001-06-20 | ||
JP186320/2001 | 2001-06-20 | ||
JP278293/2001 | 2001-09-13 | ||
JP2001278293 | 2001-09-13 | ||
PCT/JP2002/006137 WO2003000297A1 (fr) | 2001-06-20 | 2002-06-20 | Procede facilitant le transfert d'acides nucleiques |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1622831A true CN1622831A (zh) | 2005-06-01 |
CN1313158C CN1313158C (zh) | 2007-05-02 |
Family
ID=26617260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028164008A Expired - Fee Related CN1313158C (zh) | 2001-06-20 | 2002-06-20 | 促进核酸转移的方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8742091B2 (zh) |
EP (1) | EP1407787B1 (zh) |
JP (1) | JP4081436B2 (zh) |
KR (1) | KR100888566B1 (zh) |
CN (1) | CN1313158C (zh) |
AT (1) | ATE429930T1 (zh) |
CA (1) | CA2451603C (zh) |
DE (1) | DE60232149D1 (zh) |
DK (1) | DK1407787T3 (zh) |
ES (1) | ES2324525T3 (zh) |
PT (1) | PT1407787E (zh) |
WO (1) | WO2003000297A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5118285B2 (ja) * | 2000-06-20 | 2013-01-16 | 大日本住友製薬株式会社 | オリゴヌクレオチド導入製剤 |
ES2324525T3 (es) | 2001-06-20 | 2009-08-10 | Dainippon Sumitomo Pharma Co., Ltd. | Metodo para promover transferencia de acidos nucleicos. |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | NUCLEIC ACID TRANSFER METHOD |
WO2005073385A1 (ja) * | 2004-01-29 | 2005-08-11 | National Institute Of Advanced Industrial Science And Technology | 遺伝子導入効率を上昇させるための組成物および方法 |
JP2007267602A (ja) * | 2004-06-25 | 2007-10-18 | National Institute Of Advanced Industrial & Technology | 固相上で細胞に核酸を導入し、かつ、この細胞を分化誘導させるための方法および組成物 |
JP4585242B2 (ja) * | 2004-06-29 | 2010-11-24 | 株式会社高研 | 核酸導入用セルトランスフェクションアレイ |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
US7838502B2 (en) * | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
JPWO2006126600A1 (ja) * | 2005-05-25 | 2008-12-25 | 国立大学法人名古屋大学 | 血管閉塞性疾患用医薬組成物 |
EP1921153A4 (en) | 2005-07-22 | 2009-07-08 | Koken Kk | CELL TRANSFECTION ARRAY FOR USE IN TRANSFECTION |
WO2007107774A2 (en) * | 2006-03-22 | 2007-09-27 | Cartela R & D Ab | Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer |
WO2008099906A1 (ja) * | 2007-02-16 | 2008-08-21 | Anges Mg, Inc. | 歯周病、及び外科手術による歯槽骨欠損の治療剤 |
JP5789927B2 (ja) * | 2010-07-30 | 2015-10-07 | Jnc株式会社 | 放射線照射コラーゲン様ペプチドを用いた核酸導入法 |
WO2013102878A2 (en) | 2012-01-05 | 2013-07-11 | Department Of Biotechnology (Dbt) | Fat1 gene in cancer and inflammation |
WO2021041870A1 (en) * | 2019-08-30 | 2021-03-04 | University Of Florida Research Foundation | Aptamer assemblies for protein crosslinking |
WO2022120338A1 (en) * | 2020-12-03 | 2022-06-09 | University Of Florida Research Foundation, Inc. | Aptamer assemblies for protein crosslinking |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5115094B2 (zh) * | 1972-11-01 | 1976-05-14 | ||
JPH0712375B2 (ja) * | 1986-11-17 | 1995-02-15 | 株式会社高研 | 移植組成物及びその製造方法 |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
JPS6416581A (en) | 1987-07-09 | 1989-01-20 | Rikagaku Kenkyusho | Frozen animal cell and production thereof |
JPH01157388A (ja) | 1987-12-11 | 1989-06-20 | Mitsubishi Heavy Ind Ltd | 形質転換方法 |
US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5936035A (en) | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
JP3187410B2 (ja) | 1989-08-10 | 2001-07-11 | 住友製薬株式会社 | 脳内投与用徐放性製剤 |
JP2789115B2 (ja) | 1989-09-07 | 1998-08-20 | 株式会社高研 | 可溶性コラーゲンパウダーを担体とする粒状医薬徐放剤の製造方法 |
EP0779362B2 (en) | 1989-12-22 | 2012-06-13 | Laboratoires Serono SA | DNA constructs for endogenous gene activation and expression modification |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
JP2666535B2 (ja) | 1990-08-07 | 1997-10-22 | 東洋紡績株式会社 | 大腸菌のコンピテントセル化緩衝液および大腸菌のコンピテントセル化方法 |
FR2694895B1 (fr) * | 1992-08-20 | 1994-11-10 | Coletica | Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification. |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
DE69419623T2 (de) * | 1993-05-28 | 1999-12-02 | Chiron Corp | Peptidinhibitoren der urokinaserezeptor-aktivität |
EP0717617B1 (de) * | 1993-09-09 | 2000-10-25 | Schering Aktiengesellschaft | Wirkstoffe und gas enthaltende mikropartikel |
CA2140053C (en) * | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
EP0769063A1 (en) * | 1994-06-27 | 1997-04-23 | The Johns Hopkins University | Targeted gene delivery system |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
GB9422495D0 (en) | 1994-11-08 | 1995-01-04 | Medical Res Council | DNA transfer method |
US6998268B2 (en) * | 1995-07-03 | 2006-02-14 | Dainippon Sumitomo Pharma Co. Ltd. | Gene preparations |
JP3867160B2 (ja) | 1995-07-03 | 2007-01-10 | 大日本住友製薬株式会社 | 遺伝子製剤 |
CA2225998C (en) | 1995-07-03 | 2010-11-02 | Koken Co., Ltd. | Gene preparations containing biocompatible material for sustained release in gene therapy |
CN1209068A (zh) | 1995-10-23 | 1999-02-24 | 海欧制药澳大利亚有限公司 | 作为基因治疗所用的dna载体的透明质酸及治疗异常视网膜血管化的vegf反义dna |
CA2235629A1 (en) * | 1995-11-13 | 1997-05-22 | Takara Shuzo Co., Ltd. | Method for gene transfer into target cells with retrovirus |
EP2111876B1 (en) * | 1995-12-18 | 2011-09-07 | AngioDevice International GmbH | Crosslinked polymer compositions and methods for their use |
WO1997033998A1 (en) * | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US5874006A (en) * | 1996-10-31 | 1999-02-23 | Matrix Pharmaceutical, Inc. | Aseptic collagen concentration process |
US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
US6218112B1 (en) * | 1996-12-23 | 2001-04-17 | Cobra Therapeutics Limited | Optimization of gene delivery and gene delivery system |
US6524613B1 (en) * | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
IT1293088B1 (it) | 1997-07-10 | 1999-02-11 | Isi Ist Sierovaccinogeno Ital | Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in |
JPH11127843A (ja) | 1997-10-27 | 1999-05-18 | Sumitomo Bakelite Co Ltd | 培養用着色容器 |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6537813B1 (en) * | 1998-02-13 | 2003-03-25 | Selective Genetics, Inc. | Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby |
EP1623723A3 (en) | 1998-05-22 | 2006-05-10 | Dainippon Sumitomo Pharma Co., Ltd. | Stable gene formulations |
JP3587438B2 (ja) | 1999-01-14 | 2004-11-10 | 住友ベークライト株式会社 | 培養細胞凍結用マルチウェルプレート |
JP3557924B2 (ja) * | 1998-12-10 | 2004-08-25 | トヨタ自動車株式会社 | 電動機制御装置及び電動機制御方法 |
TR199901199A3 (tr) | 1999-05-31 | 2001-09-21 | Kocagoez Tanil | Bakteri transformasyon kiti |
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
EP1274410A2 (en) * | 2000-03-31 | 2003-01-15 | Trustees Of Boston University | Use of locally applied dna fragments |
JP2001335512A (ja) | 2000-05-23 | 2001-12-04 | Yamanouchi Pharmaceut Co Ltd | 遺伝子導入のための微粒子 |
JP5118285B2 (ja) * | 2000-06-20 | 2013-01-16 | 大日本住友製薬株式会社 | オリゴヌクレオチド導入製剤 |
JP2002325572A (ja) * | 2000-12-25 | 2002-11-12 | Univ Osaka | 外来物質の導入方法 |
ES2324525T3 (es) | 2001-06-20 | 2009-08-10 | Dainippon Sumitomo Pharma Co., Ltd. | Metodo para promover transferencia de acidos nucleicos. |
JP4022614B2 (ja) | 2002-03-25 | 2007-12-19 | 国立大学法人大阪大学 | 新規なバイオビーズの作製方法 |
ITMI20021444A1 (it) | 2002-07-01 | 2004-01-02 | Danieli Off Mecc | Tubo forma spire |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2003260489A1 (en) * | 2002-09-04 | 2004-03-29 | Novartis Ag | Treatment of neurological disorders by dsrna adminitration |
US20060258602A1 (en) * | 2002-09-20 | 2006-11-16 | Yukio Ando | Site-specific gene conversion promoter and gene therapeutic |
NZ540779A (en) * | 2002-11-01 | 2008-05-30 | Univ Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
CA2513623A1 (en) * | 2003-01-16 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of icam-1 |
US8227434B1 (en) * | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
EP2784090A1 (en) * | 2004-02-26 | 2014-10-01 | Baylor Research Institute | Compositions for the treatment of systemic onset juvenile idiopathic arthritis |
KR101409241B1 (ko) * | 2004-09-28 | 2014-06-24 | 쿠아크 파마수티칼스 인코퍼레이티드 | 탈모증, 급성신부전증 및 다른 질환의 치료를 위한 올리고리보뉴클레오티드 및 그것의 사용방법 |
JP2008516993A (ja) * | 2004-10-22 | 2008-05-22 | ユニベルシテ ラバル | 疼痛の治療および予防における神経膠細胞由来bdnfの調節 |
US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
WO2007082899A1 (en) * | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
WO2007144985A1 (ja) * | 2006-06-16 | 2007-12-21 | Taisho Pharmaceutical Co., Ltd. | Rpn2遺伝子発現抑制剤の用途 |
WO2008009477A2 (en) * | 2006-07-21 | 2008-01-24 | Silence Therapeutics Ag | Means for inhibiting the expression of protein kinase 3 |
US7825101B2 (en) * | 2006-08-30 | 2010-11-02 | The Board Of Trustees Of The University Of Illinois | Modulation of MLCK-L expression and uses thereof |
EP2069501A2 (en) * | 2006-10-02 | 2009-06-17 | Aprea Ab | Rna interference against wrap53 to treat hyperproliferative diseases |
US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
RU2012127772A (ru) * | 2009-12-04 | 2014-01-10 | ОПКО ОФТЭЛМИКС, ЭлЭлСи | Композиции и способы для ингибирования vegf |
-
2002
- 2002-06-20 ES ES02741206T patent/ES2324525T3/es not_active Expired - Lifetime
- 2002-06-20 WO PCT/JP2002/006137 patent/WO2003000297A1/ja active Application Filing
- 2002-06-20 JP JP2003506939A patent/JP4081436B2/ja not_active Expired - Lifetime
- 2002-06-20 EP EP02741206A patent/EP1407787B1/en not_active Expired - Lifetime
- 2002-06-20 DE DE60232149T patent/DE60232149D1/de not_active Expired - Lifetime
- 2002-06-20 PT PT02741206T patent/PT1407787E/pt unknown
- 2002-06-20 AT AT02741206T patent/ATE429930T1/de active
- 2002-06-20 US US10/481,511 patent/US8742091B2/en active Active
- 2002-06-20 CN CNB028164008A patent/CN1313158C/zh not_active Expired - Fee Related
- 2002-06-20 KR KR1020037016627A patent/KR100888566B1/ko not_active IP Right Cessation
- 2002-06-20 DK DK02741206T patent/DK1407787T3/da active
- 2002-06-20 CA CA2451603A patent/CA2451603C/en not_active Expired - Fee Related
-
2009
- 2009-09-04 US US12/554,846 patent/US20100081202A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2451603A1 (en) | 2003-01-03 |
ATE429930T1 (de) | 2009-05-15 |
DK1407787T3 (da) | 2009-06-02 |
CA2451603C (en) | 2012-07-10 |
KR20040023622A (ko) | 2004-03-18 |
US20040266004A1 (en) | 2004-12-30 |
CN1313158C (zh) | 2007-05-02 |
EP1407787A1 (en) | 2004-04-14 |
PT1407787E (pt) | 2009-07-07 |
EP1407787B1 (en) | 2009-04-29 |
WO2003000297A1 (fr) | 2003-01-03 |
EP1407787A4 (en) | 2006-02-08 |
ES2324525T3 (es) | 2009-08-10 |
DE60232149D1 (de) | 2009-06-10 |
JP4081436B2 (ja) | 2008-04-23 |
US8742091B2 (en) | 2014-06-03 |
US20100081202A1 (en) | 2010-04-01 |
JPWO2003000297A1 (ja) | 2005-04-07 |
KR100888566B1 (ko) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1313158C (zh) | 促进核酸转移的方法 | |
CN1173745C (zh) | 化学修饰的蛋氨酸酶及其在抗蛋氨酸和抗高半胱氨酸的化学治疗中的应用 | |
CA2512144C (en) | Solid surface for biomolecule delivery and high-throughput assay | |
CN1188172C (zh) | G-csf偶联物 | |
CN1305932C (zh) | 碳水化合物修饰的聚合物、其组合物及其应用 | |
CN1780851A (zh) | 将分子递送到细胞的方法和载体复合物 | |
CN1509292A (zh) | 使用c-myc反义寡聚物治疗癌症的结合的方法 | |
CN1268186A (zh) | 重组诱发剂寡核碱基校正肝细胞遗传损害的体内应用 | |
CN1845993A (zh) | 具有平端和3'修饰的干扰rna双链体 | |
CN1416462A (zh) | 人多能干细胞生长和分化的技术 | |
CN1835971A (zh) | 增加的神经胚素分泌 | |
CN1741821A (zh) | 用于癌症治疗的组合物 | |
CN101065492A (zh) | 病毒载体 | |
CN1191094C (zh) | 定向脂质体基因送递 | |
CN1826411A (zh) | 一种用于神经元细胞基因表达的启动子构建体 | |
CN1203632A (zh) | P16表达构建物及其在癌治疗中的应用 | |
CN1697879A (zh) | 利用病毒包膜导入生物分子的方法及其组合物和体系 | |
CN1173744C (zh) | 稳定的基因制剂 | |
CN101062952A (zh) | 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用 | |
CN1189482C (zh) | 一种新的血管发生抑制剂 | |
CN1220490C (zh) | 哌嗪环氧乙烷衍生物在制备用于诱导肿瘤细胞死亡的药物中的应用 | |
CN1171113A (zh) | Rb和p53基因的突变型及其应用 | |
CN1948483A (zh) | 抑制人RabJ基因表达的siRNA及其应用 | |
CN1649618A (zh) | 方法 | |
CN1525818A (zh) | 用于治疗骨性关节炎及软骨修复的亚精胺合酶抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DAINIPPON PHARMACEUTICAL CO., LTD.; APPLICANT Free format text: FORMER OWNER: SUMITOMO PHARMACEUTICALS CO., LTD.; APPLICANT Effective date: 20060224 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060224 Address after: Osaka Japan Applicant after: Dainippon Pharmaceutical Co., Ltd. Co-applicant after: Koken Co., Ltd. Address before: Osaka Japan Applicant before: Sumitomo Chemical Co., Ltd. Co-applicant before: Koken Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KOKEN CO., LTD. INDEPENDENT ADMINISTRATIVE INSTITU Free format text: FORMER OWNER: KOKEN CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100730 Address after: Osaka Japan Co-patentee after: Koken Co., Ltd. Patentee after: Dainippon Sumitomo Pharma Co., Ltd. Co-patentee after: Japan Government Address before: Osaka Japan Co-patentee before: Koken Co., Ltd. Patentee before: Dainippon Sumitomo Pharma Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070502 Termination date: 20150620 |
|
EXPY | Termination of patent right or utility model |